PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

Worst Case Consideration, page-3

  1. 316 Posts.
    lightbulb Created with Sketch. 37
    I agree that the drug itself will be second to none in the OA space
    I sincerely believe in PPS and have been a long time supporter and shareholder
    My biggest concern is Management and whilst there are a number of readers who fully support PR and his Team I have been a shareholder of a number of companies where egos and poor governance cost me a potential windfall
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.